Search

Rubitecan

Halofuginone

Collgard Biopharmaceuticals is developing halofuginone for the treatment of scleroderma and received orphan drug designation from the U.S. Food and Drug Administration in March, 2000.

(5Z,7E,9)-decatrien-2-one

An compound produced by _Fomitopsis betulina_, an edible fungus commonly called the birch polypore. Similar to [(5E,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116]

Dexchlorpheniramine

It disrupts histamine signaling by competing with histamine for cell receptor sites on effector cells. … The salt form dexchlorpheniramine maleate as the active ingredient is available as a prescription drug indicated for adjunctive therapy for allergic and anaphylactic reactions.

AK119

AK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).

Ajmaline

It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope. … It is a class Ia antiarrhythmic agent that apparently acts by changing the shape and threshold of cardiac action potentials.

Thiodigalactoside

This compound belongs to the dihexoses. These are disaccharides containing two hexose carbohydrates. … This medication is known to target galectin-1, heat-labile enterotoxin b chain, neurocan core protein, and lactose permease.

3,4-Methylenedioxy-N-isopropylamphetamine

MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).

Poloxamine 1304

Poloxamine 1304 is under investigation in clinical trial NCT00483795 (Pilot Evaluation of Two Multipurpose Solutions in Regards to Corneal Staining).

Abetimus

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.